1. Home
  2. ALXO vs EARN Comparison

ALXO vs EARN Comparison

Compare ALXO & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.79

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$4.49

Market Cap

169.8M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALXO
EARN
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
205.9M
169.8M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
ALXO
EARN
Price
$1.79
$4.49
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$3.50
$5.38
AVG Volume (30 Days)
1.4M
381.3K
Earning Date
05-08-2026
06-16-2026
Dividend Yield
N/A
20.51%
EPS Growth
26.36
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$7.69
Revenue Next Year
N/A
$19.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$4.27
52 Week High
$2.66
$6.08

Technical Indicators

Market Signals
Indicator
ALXO
EARN
Relative Strength Index (RSI) 54.99 42.33
Support Level $1.54 $4.27
Resistance Level $2.27 $4.78
Average True Range (ATR) 0.12 0.10
MACD 0.03 -0.02
Stochastic Oscillator 97.62 32.61

Price Performance

Historical Comparison
ALXO
EARN

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.

Share on Social Networks: